Q&A with John Carey: Peeling back the label on cholesterol drugs
John Carey, a 20-year veteran at BusinessWeek, wrote a story that set the pharmaceutical world on its ear in January 2008. Titled "Do Cholesterol Drugs Do Any Good?," the article systematically broke...
View ArticleQ&A with Dr. Daniel Carlat: Finding an independent voice in a...
Even in his infamy, Dr. Daniel Carlat, founder of The Carlat Psychiatry Report, is popular with drug companies. Carlat was invited recently by Schering-Plough to help promote a new drug.
View ArticleThe Mittleman Files, Part 2: Just another day on the ghostwriting assembly line
Putting together a scientific research paper should be a different process than building a Ford Taurus or making a Big Mac.For the drug companies and their ghostwriting partners, it isn’t.
View ArticleThe Markingson Files: Conflicts of interest in clinical trials should be...
It can be uncomfortable asking people about their finances. In journalism, though, there is an obligation not only to ask, but to ask for proof — especially with clinical trials.
View ArticleFull Disclosure: Universities Should Make Ghostwriting Disappear
Shannon Brownlee offers a not-so-modest proposal for universities to stamp out pharma ghostwriting benefiting researchers.
View ArticleIt's Complicated: Taking Conflict of Interest Beyond Pharma Payments to...
I wrote a piece recently for Health News Review about conflicts of interest. The original post is below, followed by more great examples of writers describing unexpected conflicts in detail.
View ArticleQ&A with Leigh Turner: Tracking Medical Tourism Consequences
Bioethicist Leigh Turner, recently under fire from a stem cell company he criticized for ethical problems, talks about his research on medical tourism.
View Article